123 related articles for article (PubMed ID: 26531748)
1. From prospective biobanking to precision medicine: BIO-RAIDs - an EU study protocol in cervical cancer.
Ngo C; Samuels S; Bagrintseva K; Slocker A; Hupé P; Kenter G; Popovic M; Samet N; Tresca P; von der Leyen H; Deutsch E; Rouzier R; Belin L; Kamal M; Scholl S;
BMC Cancer; 2015 Nov; 15():842. PubMed ID: 26531748
[TBL] [Abstract][Full Text] [Related]
2. Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Scholl S; Popovic M; de la Rochefordiere A; Girard E; Dureau S; Mandic A; Koprivsek K; Samet N; Craina M; Margan M; Samuels S; Zijlmans H; Kenter G; Hillemanns P; Dema S; Dema A; Malenkovic G; Djuran B; Floquet A; Garbay D; Guyon F; Colombo PE; Fabbro M; Kerr C; Ngo C; Lecuru F; Campo ERD; Coutant C; Marchal F; Mesgouez-Nebout N; Fourchotte V; Feron JG; Morice P; Deutsch E; Wimberger P; Classe JM; Gleeson N; von der Leyen H; Minsat M; Dubot C; Gestraud P; Kereszt A; Nagy I; Balint B; Berns E; Jordanova E; Saint-Jorre N; Savignoni A; Servant N; Hupe P; de Koning L; Fumoleau P; Rouzier R; Kamal M
EBioMedicine; 2019 May; 43():253-260. PubMed ID: 30952619
[TBL] [Abstract][Full Text] [Related]
3. Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study.
Samuels S; Balint B; von der Leyen H; Hupé P; de Koning L; Kamoun C; Luscap-Rondof W; Wittkop U; Bagrintseva K; Popovic M; Kereszt A; Berns E; Kenter GG; Jordanova ES; Kamal M; Scholl S
Br J Cancer; 2016 Dec; 115(12):1575-1583. PubMed ID: 27875525
[TBL] [Abstract][Full Text] [Related]
4. Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer.
Scholl SM; Beal J; de Koning L; Girard E; Popovic M; de la Rochefordière A; Lecuru F; Fourchotte V; Ngo C; Floquet A; Berns EM; Kenter G; Gestraud P; von der Leyen H; Lecerf C; Puard V; Roman SR; Latouche A; Kereszt A; Balint B; Rouzier R; Kamal M
EBioMedicine; 2020 Nov; 61():103049. PubMed ID: 33096476
[TBL] [Abstract][Full Text] [Related]
5. Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.
Bins S; Cirkel GA; Gadellaa-Van Hooijdonk CG; Weeber F; Numan IJ; Bruggink AH; van Diest PJ; Willems SM; Veldhuis WB; van den Heuvel MM; de Knegt RJ; Koudijs MJ; van Werkhoven E; Mathijssen RH; Cuppen E; Sleijfer S; Schellens JH; Voest EE; Langenberg MH; de Jonge MJ; Steeghs N; Lolkema MP
Oncologist; 2017 Jan; 22(1):33-40. PubMed ID: 27662884
[TBL] [Abstract][Full Text] [Related]
6. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.
Gonçalves A; Bertucci F; Guille A; Garnier S; Adelaide J; Carbuccia N; Cabaud O; Finetti P; Brunelle S; Piana G; Tomassin-Piana J; Paciencia M; Lambaudie E; Popovici C; Sabatier R; Tarpin C; Provansal M; Extra JM; Eisinger F; Sobol H; Viens P; Lopez M; Ginestier C; Charafe-Jauffret E; Chaffanet M; Birnbaum D
Oncotarget; 2016 Nov; 7(48):79428-79441. PubMed ID: 27765906
[TBL] [Abstract][Full Text] [Related]
7. Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.
Muller E; Brault B; Holmes A; Legros A; Jeannot E; Campitelli M; Rousselin A; Goardon N; Frébourg T; Krieger S; Crouet H; Nicolas A; Sastre X; Vaur D; Castéra L
Cancer Med; 2015 Oct; 4(10):1484-93. PubMed ID: 26155992
[TBL] [Abstract][Full Text] [Related]
8. Plasma miR-127 and miR-218 Might Serve as Potential Biomarkers for Cervical Cancer.
You W; Wang Y; Zheng J
Reprod Sci; 2015 Aug; 22(8):1037-41. PubMed ID: 25701838
[TBL] [Abstract][Full Text] [Related]
9. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
10. Emerging biomarkers and molecular targets for precision medicine in cervical cancer.
Garg P; Krishna M; Subbalakshmi AR; Ramisetty S; Mohanty A; Kulkarni P; Horne D; Salgia R; Singhal SS
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189106. PubMed ID: 38701936
[TBL] [Abstract][Full Text] [Related]
11. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.
Kruglyak KM; Lin E; Ong FS
Adv Exp Med Biol; 2016; 890():123-36. PubMed ID: 26703802
[TBL] [Abstract][Full Text] [Related]
12. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
Syn NL; Yong WP; Goh BC; Lee SC
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
[TBL] [Abstract][Full Text] [Related]
13. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.
Tran B; Brown AM; Bedard PL; Winquist E; Goss GD; Hotte SJ; Welch SA; Hirte HW; Zhang T; Stein LD; Ferretti V; Watt S; Jiao W; Ng K; Ghai S; Shaw P; Petrocelli T; Hudson TJ; Neel BG; Onetto N; Siu LL; McPherson JD; Kamel-Reid S; Dancey JE
Int J Cancer; 2013 Apr; 132(7):1547-55. PubMed ID: 22948899
[TBL] [Abstract][Full Text] [Related]
15. Precision medicine for advanced prostate cancer.
Mullane SA; Van Allen EM
Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs are involved in cervical cancer development, progression, clinical outcome and improvement treatment response (Review).
González-Quintana V; Palma-Berré L; Campos-Parra AD; López-Urrutia E; Peralta-Zaragoza O; Vazquez-Romo R; Pérez-Plasencia C
Oncol Rep; 2016 Jan; 35(1):3-12. PubMed ID: 26530778
[TBL] [Abstract][Full Text] [Related]
17. Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer.
Zhang Y; Zhang D; Wang F; Xu D; Guo Y; Cui W
Sci Rep; 2015 Dec; 5():17942. PubMed ID: 26656154
[TBL] [Abstract][Full Text] [Related]
18. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of elevated pretreatment carcinoembryonic antigen in patients with advanced squamous cell carcinoma of the uterine cervix.
Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Yang SN; Lin FJ
Tumour Biol; 2008; 29(4):255-61. PubMed ID: 18781097
[TBL] [Abstract][Full Text] [Related]
20. High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.
Tan SH; Sapari NS; Miao H; Hartman M; Loh M; Chng WJ; Iau P; Buhari SA; Soong R; Lee SC
PLoS One; 2015; 10(12):e0142466. PubMed ID: 26630576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
